Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Positive allosteric modulators for melanocortin receptors
US9744171B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9744171-B2 |
| Application number | US-201314383715-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 6, 2013 |
| Priority date | Mar 6, 2012 |
| Publication date | Aug 29, 2017 |
| Grant date | Aug 29, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric modulator.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating obesity in a subject, comprising administering a therapeutically effective amount of a pharmaceutical composition to the subject including a compound selected from the group consisting of and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. 2. The method of claim 1 , wherein the obesity is dietary obesity. 3. The method of claim 1 , wherein the obesity is mediated by dysfunctional melanocortin receptor signaling. 4. The method of claim 3 , wherein the obesity is mediated by dysfunctional melanocortin-4 receptor (MC4R) signaling. 5. The method of claim 1 , wherein the obesity is severe or morbid obesity due to MC4R haploinsufficiency. 6. The method of claim 5 , wherein the obesity is melanocortin obesity syndrome. 7. The method of claim 1 , wherein the compound is and pharmaceutically acceptable salts thereof. 8. The method of claim 1 , wherein the compound is and pharmaceutically acceptable salts thereof. 9. The method of claim 1 , wherein the compound is and pharmaceutically acceptable salts thereof. 10. The method of claim 1 , wherein the compound is and pharmaceutically acceptable salts thereof.
Assignees
Inventors
Classifications
with aryl radicals directly attached to ring atoms · CPC title
from vertebrates · CPC title
Quinolines; Isoquinolines · CPC title
1,3-Thiazoles · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9744171B2 cover?
- Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric…
- Who is the assignee on this patent?
- Univ Vanderbilt
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).